Stopping ‘cut-and-run’ DNA errors to help treat leukaemia and predict relapse
Towards inhibiting cut-and-run: An aberrant V(D)J recombination reaction that leads to lymphoid cancers
Using artificial intelligence to diagnose brain tumours
Moving Artificial Intelligence of Functional Imaging for children’s tumours into a multi-centre environment through a Clinical Decision Support System
Understanding how some leukaemia cells survive treatment and cause a relapse
Understanding and therapeutically exploiting clonal evolution in chemo-resistant acute lymphoblastic leukaemia
Electrotherapy for childhood brain tumours
Electrotherapy for childhood brain tumours
A new way of treating poor prognosis Wilms’ tumour
Targeting gain of function p53 in poor prognosis Wilms' tumour via histone methyltransferase inhibition
Killing dormant leukaemia cells to stop relapse
Targeting refractory and dormant stem cells in childhood leukaemia
Reducing pain caused as a side effect of vincristine chemotherapy
Can we reduce or eliminate the sensory nerve damage caused by vincristine chemotherapy? Potential novel adjunct neuroprotective/analgesic therapies.
Improving our understanding of immunotherapy in high-risk neuroblastoma
Understanding and improving the mechanism of action of anti-GD2 monoclonal antibody therapy in neuroblastoma
Phase II clinical trial: Can a new drug help treat relapsed or refractory (not responding to treatment) ALK+ anaplastic large cell lymphoma?
NIVO-ALCL - Phase II trial of nivolumab for paediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2)